Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aerie Pharmaceuticals (NQ: AERI )

8.910 +1.540 (+20.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 5, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aerie Pharmaceuticals

< Previous 1 2 Next >
Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces New Employee Inducement Grant
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022 at 5:00 p.m. ET
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., April 22-26, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. ET
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical Officer
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022 at 5:00 p.m. ET
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Reports Inducement Grant to Chief Executive Officer Under Nasdaq Listing Rule 5635(c)(4)
From Aerie Pharmaceuticals
Via Business Wire
Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November 4, 2021
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Glaucoma Innovation Showcase
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation Showcase
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces Presentation at the 39th Annual Scientific Meeting of the American Society of Retina Specialists
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b Clinical Study for the Treatment of Dry Eye Disease
From Aerie Pharmaceuticals
Via Business Wire
Aerie Pharmaceuticals Announces Appointment of Carolyn McAuliffe, Senior Director, Communications
From Aerie Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.